Anfield Capital Management LLC Buys Shares of 155,644 Roivant Sciences Ltd. $ROIV

Anfield Capital Management LLC bought a new stake in Roivant Sciences Ltd. (NASDAQ:ROIV) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 155,644 shares of the company’s stock, valued at approximately $2,355,000.

Several other large investors have also recently made changes to their positions in the company. Goldman Sachs Group Inc. lifted its holdings in Roivant Sciences by 15.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 2,433,386 shares of the company’s stock valued at $24,553,000 after purchasing an additional 324,764 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of Roivant Sciences by 1.4% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,445,807 shares of the company’s stock valued at $24,678,000 after buying an additional 34,341 shares during the last quarter. CWM LLC raised its position in shares of Roivant Sciences by 44.6% in the second quarter. CWM LLC now owns 2,984 shares of the company’s stock valued at $34,000 after buying an additional 920 shares during the last quarter. Envestnet Asset Management Inc. lifted its stake in shares of Roivant Sciences by 30.2% in the second quarter. Envestnet Asset Management Inc. now owns 42,810 shares of the company’s stock worth $482,000 after buying an additional 9,936 shares in the last quarter. Finally, Transcend Capital Advisors LLC acquired a new position in Roivant Sciences during the second quarter worth about $187,000. 64.76% of the stock is currently owned by hedge funds and other institutional investors.

Roivant Sciences Price Performance

Shares of ROIV opened at $28.94 on Friday. The firm has a 50-day simple moving average of $23.93 and a two-hundred day simple moving average of $19.44. The stock has a market cap of $20.71 billion, a PE ratio of -24.74 and a beta of 1.22. Roivant Sciences Ltd. has a 1-year low of $8.73 and a 1-year high of $29.20.

Insider Transactions at Roivant Sciences

In related news, Director Daniel Allen Gold sold 375,784 shares of the business’s stock in a transaction on Friday, February 13th. The stock was sold at an average price of $26.50, for a total value of $9,958,276.00. Following the sale, the director owned 15,127,329 shares in the company, valued at approximately $400,874,218.50. The trade was a 2.42% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Mayukh Sukhatme sold 339,441 shares of the firm’s stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $26.47, for a total value of $8,985,003.27. Following the transaction, the insider owned 19,148,664 shares of the company’s stock, valued at $506,865,136.08. This trade represents a 1.74% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 13,318,014 shares of company stock worth $315,727,023 in the last ninety days. 10.80% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of research firms have commented on ROIV. Jefferies Financial Group reiterated a “buy” rating and issued a $30.00 price objective on shares of Roivant Sciences in a report on Monday, February 9th. TD Cowen reaffirmed a “buy” rating on shares of Roivant Sciences in a report on Saturday, February 7th. Leerink Partners lifted their price objective on Roivant Sciences from $29.00 to $32.00 and gave the stock an “outperform” rating in a research report on Monday, December 15th. Citigroup upped their target price on Roivant Sciences from $26.00 to $35.00 and gave the company a “buy” rating in a report on Tuesday, February 10th. Finally, Guggenheim raised their target price on Roivant Sciences from $28.00 to $30.00 and gave the stock a “buy” rating in a research note on Monday, February 9th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $28.69.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.